Takeda announced that Orzeyful (oveporexton) is now available by prescription in the United States for the treatment of narcolepsy type 1 in adults. Orzeyful, an oral orexin receptor 2 agonist, is the first and only FDA-approved therapy that targets the underlying orexin deficiency associated with narcolepsy type 1 rather than individual symptoms.
The Drug Enforcement Administration has classified Orzeyful as a Schedule IV controlled substance (CIV), allowing the medication to be commercially launched following its FDA approval in August 2026.
According to Takeda, Orzeyful is available by prescription and will be dispensed across the U.S. through Accredo Specialty Pharmacy. Takeda offers patient support programs to help eligible individuals understand coverage and assistance options.
For more information about the medication and data supporting its approval, read the AASM news article, “FDA approves Orzeyful for narcolepsy type 1 in adults.”
Read more industry news from the AASM.
